^
BIOMARKER:

NPM1 mutation

i
Other names: Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin), Testicular Tissue Protein Li 128, Nucleolar Protein NO38, Numatrin, NPM1, Nucleophosmin 1, Nucleophosmin/Nucleoplasmin Family, Member 1, Nucleolar Phosphoprotein B23
Entrez ID:
Related biomarkers:
NPM1 mutation
AML
venetoclax
Sensitive: B - Late Trials
NPM1 mutation
AML
gemtuzumab ozogamicin
Sensitive: B - Late Trials
NPM1 mutation
AML
cytarabine
Sensitive: B - Late Trials
NPM1 mutation
AML
SNDX-5613
Sensitive: B - Late Trials
NPM1 mutation
AML
dactinomycin
Sensitive: C2 – Inclusion Criteria
NPM1 mutation
AML
GS-9973
Sensitive: C2 – Inclusion Criteria
NPM1 mutation
AML
sorafenib
Sensitive: C2 – Inclusion Criteria
NPM1 mutation
AML
azacitidine
Sensitive: C2 – Inclusion Criteria
NPM1 mutation
AML
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
NPM1 mutation
AML
cytarabine
Sensitive: C3 – Early Trials
NPM1 mutation
AML
FLAI
Sensitive: C3 – Early Trials
NPM1 mutation
AML
cytarabine + idarubicin hydrochloride
Sensitive: C3 – Early Trials
NPM1 mutation
CMML
venetoclax
Sensitive: C3 – Early Trials
NPM1 mutation
MDS
decitabine
Sensitive: C3 – Early Trials
NPM1 mutation
AML
quizartinib
Sensitive: C3 – Early Trials
NPM1 mutation
AML
venetoclax + ruxolitinib
Sensitive: C3 – Early Trials
NPM1 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
NPM1 mutation
AML
cytarabine + clofarabine
Sensitive: C3 – Early Trials
NPM1 mutation
AML
cytarabine + cladribine
Sensitive: C3 – Early Trials
NPM1 mutation
AML
decitabine + clofarabine
Sensitive: C3 – Early Trials
NPM1 mutation
AML
decitabine + cladribine
Sensitive: C3 – Early Trials
NPM1 mutation
AML
PD1 inhibitor
Sensitive: C3 – Early Trials
NPM1 mutation
AML
ABBV-744
Sensitive: D – Preclinical
NPM1 mutation
AML
venetoclax + IACS-010759
Sensitive: D – Preclinical
NPM1 mutation
Leukemia
EPZ004777
Sensitive: D – Preclinical
NPM1 mutation
AML
NSC348884
Sensitive: D – Preclinical
NPM1 mutation
AML
DS-M1
Sensitive: D – Preclinical